•  
  •  
 

Lynchburg Journal of Medical Science

Lynchburg Journal of Medical Science

Specialty

Hematology/Oncology

Advisor

Dr. Thomas Colletti, DHSc, PA-C, DFAAPA

Abstract

Purpose: The purpose of this article is to discuss a case presentation of a rare form of acquired Hemophagocytic Lymphohistiocytosis (HLH) and review the standard of care in addition to current therapeutic options for the disease.

Method: A PubMed literature search conducted with search terms hemophagocytic lymphohistiocytosis, guidelines, survival, treatment, and EBV, allowed for the review and reference to nine applicable sources for this case presentation.

Results: Increased observation of young adults with relapsed or refractory secondary HLH is needed to evaluate for remission with a new monoclonal antibody (mAb) therapy versus standard of care chemotherapeutic protocols with stem cell transplant.

Conclusion: The patient is currently under active surveillance for relapse and possible treatment with emapalumab for secondary HLH to determine if remission-cure can be achieved. Emapalumab is a monoclonal antibody recently approved to treat relapsed and refractory sHLH.

Restricted

Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.

Off-campus users can also use 'Off-campus Download' button above for access.

Share

COinS